N
Nicole M. Scharenborg
Researcher at Radboud University Nijmegen
Publications - 27
Citations - 2856
Nicole M. Scharenborg is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Dendritic cell & Antigen-presenting cell. The author has an hindex of 22, co-authored 27 publications receiving 2694 citations. Previous affiliations of Nicole M. Scharenborg include Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal Article
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state
I. Jolanda M. de Vries,Daniëlle J. E. B. Krooshoop,Nicole M. Scharenborg,W. Joost Lesterhuis,J. Heleen S. Diepstra,Goos N.P. van Muijen,S. P. Strijk,Theo J.M. Ruers,Otto C. Boerman,Wim J.G. Oyen,Gosse J. Adema,Cornelis J. A. Punt,Carl G. Figdor +12 more
TL;DR: It is demonstrated that in vitro-generated mature, but not immature dendritic cells, efficiently migrate into the T-cell areas of lymph nodes of melanoma patients.
Journal Article
Maturation of Dendritic Cells Is a Prerequisite for Inducing Immune Responses in Advanced Melanoma Patients
I. Jolanda M. de Vries,W. Joost Lesterhuis,Nicole M. Scharenborg,Linda P. H. Engelen,Dirk J. Ruiter,Marie-Jeanne P. Gerritsen,Sandra Croockewit,Cedrik M. Britten,Ruurd Torensma,Gosse J. Adema,Carl G. Figdor,Cornelis J. A. Punt +11 more
TL;DR: It is concluded that mature DC are superior to immature DC in the induction of immunological responses in melanoma patients, which may translate into improved clinical results.
Journal ArticleDOI
Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
Joannes F M Jacobs,Cornelis J. A. Punt,W. Joost Lesterhuis,Roger P.M. Sutmuller,H. Mary-lène H. Brouwer,Nicole M. Scharenborg,Ina S. Klasen,Luuk B. Hilbrands,Carl G. Figdor,I. Jolanda M. de Vries,Gosse J. Adema +10 more
TL;DR: The results indicate that for immunotherapeutic benefit of transient Treg depletion, timing and dosing as well as Treg specificity are extremely important.
Journal ArticleDOI
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
Gerty Schreibelt,Kalijn F. Bol,Harm Westdorp,Florian Wimmers,Erik H.J.G. Aarntzen,Tjitske Duiveman-de Boer,Mandy W.M.M. van de Rakt,Nicole M. Scharenborg,Annemiek J. de Boer,Jeanette M. Pots,Michel A.M. Olde Nordkamp,Tom G. M. van Oorschot,Jurjen Tel,Gregor Winkels,Katja Petry,Willeke A. M. Blokx,Michelle M. van Rossum,Marieke E. B. Welzen,Roel Mus,Sandra Croockewit,Rutger H. T. Koornstra,Joannes F M Jacobs,Sander Kelderman,Christian U. Blank,Winald R. Gerritsen,Cornelis J. A. Punt,Carl G. Figdor,I. Jolanda M. de Vries +27 more
TL;DR: It is shown that vaccination of metastatic melanoma patients with primary myeloid DCs is feasible and safe and results in induction of effective antitumor immune responses that coincide with improved progression-free survival.
Journal ArticleDOI
Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome
I. Jolanda M. de Vries,Monique R. Bernsen,W. Joost Lesterhuis,Nicole M. Scharenborg,S. P. Strijk,Marie-Jeanne P. Gerritsen,Dirk J. Ruiter,Carl G. Figdor,Cornelis J. A. Punt,Gosse J. Adema +9 more
TL;DR: A direct correlation between the presence of DC vaccine-related T cells in the DTH biopsies of stage IV melanoma patients and a positive clinical outcome is observed, demonstrating the potency of this novel approach in the monitoring of vaccination studies in cancer patients.